We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Genetic Variant as a Selection Marker for Anti-Prostate Stem Cell Antigen Immunotherapy of Bladder Cancer.
- Authors
Kohaar, Indu; Porter-Gill, Patricia; Lenz, Petra; Yi-Ping Fu; Mumy, Adam; Wei Tang; Apolo, Andrea B.; Rothman, Nathaniel; Baris, Dalsu; Schned, Alan R.; Ylaya, Kris; Schwenn, Molly; Johnson, Alison; Jones, Michael; Kida, Masatoshi; Silverman, Debra T.; Hewitt, Stephen M.; Moore, Lee E.; Prokunina-Olsson, Ludmila
- Abstract
A monoclonal antibody against prostate stem cell antigen (PSCA) has emerged as a novel cancer therapy currently being tested in clinical trials for prostate and pancreatic cancers, but this treatment is likely to be efficient only in patients with PSCA-expressing tumors. The present study demonstrates that a genetic variant (rs2294008) discovered by bladder cancer genome-wide association studies is a strong predictor of PSCA protein expression in bladder tumors, as measured by two-sided multivariable linear regression (P = 6.46x10-11; n = 278). The association pattern is similar in non-muscle-invasive tumors, stages Ta (P = 3.10x10-5; n = 173) and T1 (P = 2.64x10-5; n = 60), and muscle-invasive tumors, stages T2 (P=.01; n = 23) andT3/4 (P=.03; n = 22). The study suggests that anti-PSCA immunotherapy might be beneficial for bladder cancer patients with high tumor PSCA expression, which is statistically significantly associated with the presence of CT and TT genotypes of a common genetic variant, rs2294008. Future clinical studies will be needed to validate PSCA as a therapeutic target for bladder cancer.
- Subjects
BLADDER cancer treatment; IMMUNOTHERAPY; STEM cell treatment; ANTIGENS; CANCER chemotherapy
- Publication
JNCI: Journal of the National Cancer Institute, 2013, Vol 105, Issue 1, p69
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djs458